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Photosensitive retinal ganglion cells
a  b  s  t  r  a  c  t
In  two  recent  reports,  melanopsin  gene  variations  were  associated  with  seasonal  affective  disorder  (SAD),
and  in  changes  in the  timing  of  sleep  and  activity  in healthy  individuals.  New  studies  have  deepened  our
understanding  of  the retinohypothalamic  tract,  which  translates  environmental  light  received  by the
retina  into  neural  signals  sent  to a  set  of  nonvisual  nuclei  in  the  brain  that  are responsible  for  functions
other  than  sight  including  circadian,  neuroendocrine  and  neurobehavioral  regulation.  Because  this  path-
way mediates  seasonal  changes  in  physiology,  behavior,  and  mood,  individual  variations  in the pathway
may explain  why  approximately  1–2% of  the  North  American  population  develops  mood  disorders  with
a  seasonal  pattern  (i.e.,  Major  Depressive  and  Bipolar  Disorders  with  a seasonal  pattern,  also  known  as
seasonal affective  disorder/SAD).  Components  of  depression  including  mood  changes,  sleep  patterns,
appetite,  and  cognitive  performance  can  be  affected  by  the  biological  and  behavioral  responses  to  light.
Speciﬁcally,  variations  in  the  gene  sequence  for the  retinal  photopigment,  melanopsin,  may  be  respon-
sible  for  signiﬁcant  increased  risk  for mood  disorders  with  a seasonal  pattern,  and  may  do  so  by  leading
to  changes  in  activity  and  sleep  timing  in winter.  The  retinal  sensitivity  of  SAD  is hypothesized  to  be
decreased  compared  to  controls,  and  that  further  decrements  in  winter  light  levels  may  combine  to  trig-
ger  depression  in  winter.  Here  we  outline  steps  for  new  research  to  address  the  possible  role  of  melanopsin
in  seasonal  affective  disorder  including  chromatic  pupillometry  designed  to measure  the  sensitivity  of
melanopsin  containing  retinal  ganglion  cells.
© 2013  Elsevier  Ltd.  All  rights  reserved.
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1. Introduction
The recently described melanopsin light input pathway may
contribute to our understanding of seasonal affective disorder
(SAD). SAD involves recurrent depressive episodes in the fall or
winter months with remission or a change to mania or hypomania
in the spring (Rosenthal et al., 1984). SAD is common and perva-
sive, affecting 0.8–2.2% of the North American population (Lam and
Levitt, 1999). Three evidence-based treatments exist (i.e., antide-
pressant medications, light therapy, and psychotherapy), but not
all SAD patients respond fully to these treatments. Incorporating
research on melanopsin has the potential to improve our under-
standing of the etiology of SAD by identifying a link between gene
variations, biomarkers, and risk for depression, and also to suggest
new and individually tailored treatments.
The role of melanopsin in SAD has not been thoroughly explored,
although the rationale for further investigation is strong. The reg-
ular winter recurrence of episodes, seasonal biological changes,
and the beneﬁt of light therapy for SAD suggest that its etiology
is rooted in abnormal responses to light. Shorter photoperiods in
winter may  trigger SAD in susceptible individuals, analogous to
other mammalian seasonal responses. An abnormal response to
light may  be mediated by abnormal retinal signaling (Wehr et al.,
2001), termed the retinal subsensitivity hypothesis of SAD (Hebert
et al., 2002). Such hypotheses were conceived prior to the descrip-
tion of melanopsin and its role in circadian, neuroendocrine and
neurobehavioral processes. Abnormal retinal responses to light
could be due to differences in the retinohypothalamic pathway,
comprised of retinal ganglion cells that contain the photosensitive
protein melanopsin. Some SAD patients differ from controls based
on sequence variation in the melanopsin gene (Roecklein et al.,
2009). Additionally, those variations are associated with seasonal
changes in sleep timing and chronotype (Roecklein et al., 2012).
Although melanopsin variations may  hypothetically be the physio-
logical basis underlying the retinal subsensitivity hypothesis, other
possibilities are discussed as well.
Below, we brieﬂy summarize the neurobiology and function
of the melanopsin system, which has recently been reviewed
by others (e.g., Do and Yau, 2010). Although the implications of
the melanopsin system for human eye disease and human sleep
and cognitive performance have been described elsewhere (e.g.,
Kawasaki and Kardon, 2007), this review focuses on the potential
role of melanopsin in SAD and possible treatment implications.
1.1. Circadian, neuroendocrine and neurobehavioral responses to
light
The discovery of melanopsin conﬁrmed that rods and cones are
not the only photoreceptors involved in circadian, neuroendocrine,
and neurobehavioral responses to light (Provencio et al., 1998).
Melanopsin is found in intrinsically photosensitive retinal ganglion
cells (ipRGCs), which are photosensitive even when input from rods
and cones is pharmacologically blocked (Berson et al., 2002; Hattar
et al., 2002; Gooley et al., 2001). Although melanopsin is found
in only 2% of ganglion cells, their dendrites form a “photorecep-
tive net” across the retina (Berson et al., 2002; Hattar et al., 2002;
Gooley et al., 2001; Provencio et al., 2002). Additionally, melanopsin
cell responses increase with light intensity with a high threshold,
and they are slow to initiate and terminate nerve impulses, qual-
ities making them ideal for measuring gross environmental light
levels rather than forming crisp images (Berson et al., 2002, 2010;
Dacey et al., 2005; Pu, 2000). Melanopsin signaling pathways, as
established in animal models, have complex inputs from bipolar,
amacrine, rod, and cone cells, and multiple projections (Do and Yau,
2010). If conserved in humans, the retinorecipient areas that may
be important in SAD include the suprachiasmatic nucleus (SCN) and
intergeniculate leaﬂet (circadian regulation), the lateral hypothala-
mus  (energy homeostasis), and the ventral subparaventricular zone
and preoptic nucleus (sleep promotion and regulation; Graham
et al., 2008; Hannibal and Fahrenkrug, 2004; Hattar et al., 2002,
2006).
1.2. Gene variations and human behavior
We have reported melanopsin gene (OPN4) associations in two
populations. In a study of 220 individuals, those with the TT
genotype at P10L (rs2675703) had a 5.6 times increased risk of
SAD (Roecklein et al., 2009). This association was retested in a
healthy sample to remove the effect of mood disorder symptoms.
In 268 healthy individuals, the effects of P10L TT genotype and day
length interacted to predict earlier bedtime when individuals were
assessed on shorter days, and later bedtime when individuals were
assessed on longer days (Roecklein et al., 2012). If replicated, and
found in SAD as well, these data may  indicate a speciﬁc etiologi-
cal relationship between P10L, changes in sleep timing, and SAD.
To date, however, these are the only two  SNP-association studies
showing a link between melanopsin and SAD in the ﬁrst study, and
between melanopsin and seasonal changes in sleep timing in the
second study. Replication, and other studies designed to evaluate
the role of melanopsin in SAD are needed. Such studies will greatly
beneﬁt from the basic science literature describing the functions of
melanopsin and melanopsin containing cells.
1.3. Functions of melanopsin
Functions that are controlled by photic stimulation of the
melanopsin system include the pupil light reﬂex, circadian pho-
toentrainment, sleep regulation, acute suppression of plasma
melatonin, and acute effects of light on cognitive performance,
although the expression of these functions varies between humans
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Table  1
Summary of melanopsin ﬁndings in human research.
Authors Year Participants Findings
Thapan et al. 2001 22 Healthy individuals 459 nm light maximally suppressed melatonin release
Brainard et al. 2001 72 Healthy individuals 446–477 nm most effective in suppressing nighttime melatonin release
Lockely et al. 2003 16 Healthy individuals 460 nm light more effective than 555 nm for phase shift and melatonin
suppression
Phipps-Nelson et al. 2003 16 Healthy individuals 10,000 lx light (ﬂuorescent) reduces subjective sleepiness and improves
psychomotor performance compared to dim 1000 lx (incandescent)
Cajochen et al. 2005 10 Healthy men  460 nm light more effective than 550 nm light for melatonin suppression,
alerting response, and responses of body temperature and heart rate
Zaidi  et al. 2007 2 Visually impaired individuals 480 nm peak sensitivity for melatonin suppression, phase shifts, acute increase
in  alertness, pupillary constriction, and stimulus detection
An  et al. 2009 12 Healthy individuals 458 nm more effective than 550 nm light for cognitive functioning and arousal
level, 458 nm light produced larger effects at nighttime
Roecklein et al. 2009 130 SAD 90 healthy controls rs2675703 (P10L) T/T variation higher in SAD than controls
Gamlin et al. 2007 2 Healthy men  Sustained post-stimulus pupilloconstriction (PIPR) maximally sensitive to
482 nm
Brainard et al. 2008 26 Healthy individuals 460 nm light optimal for melatonin suppression
Mure  et al. 2009 12 Healthy individuals Sustained pupil constriction and PIPR maximally sensitive to 460–480 nm,
evidence for melanopsin bistability
Revell et al. 2010 12 Healthy men  479 nm light more effective for melatonin suppression, but cognitive
performance more sensitive to other wavelengths indicating involvement of
multiple photoreceptors
Kankipati et al. 2010 37 Healthy individuals PIPR evident in response to 470 nm but not 623 nm stimulus
Gooley et al. 2010 48 Healthy individuals Melatonin suppression tests indicate that melanopsin is primarily responsive
to  long duration, high irradiance stimuli
McDougal and Gamlin 2010 6 Healthy individuals Cone photoreceptors adapt over 30 s, and rods do not respond at high
irradiances, such that long-duration high irradiance stimuli induce melanopsin
responses
Kankipati et al. 2011 16 Glaucoma patients 19
matched controls
PIPR lower in glaucoma patients compared to matched controls, PIPR decrease
correlates with glaucomatous neuropathy
Kardon et al. 2011 32 Retinitis pigmentosa (RP)
patients 43 healthy controls
RP patients had a more pronounced PIPR compared to controls
Zele  et al. 2011 11 Healthy individuals PIPR maximally evident at CT 15, ∼2 hr 40 min prior to DLMO
Gagne et al. 2011 10 SAD 10 healthy controls SAD and controls did not differ in ERG after 1 h red or blue stimulus, ERGs
were lower after blue in both groups
Gagne and Hebert 2011 12 SAD 11 healthy controls ERG decrease after 10,000 lx 1-hour exposure in summer and winter in SAD
but not controls, did not differ by wavelength
Roecklein et al. 2012 234 Healthy individuals rs2675703 (P10L) T/T variation interacts with photoperiod to predict
chronotype and sleep timing
SAD: seasonal affective disorder. PIPR – post-illumination pupil response. DLMO – Dim light melatonin onset. See Section 3.5 regarding studies on blue or blue-enriched light
therapy in SAD.
and other mammals. In general, melanopsin knockout mice
(Opn4−/−) show impairment in many of these measures, indicating
that ipRGCs are important for encoding light intensity for ani-
mal  biological and behavioral responses (Hattar et al., 2003). Some
or all of these functions may  be relevant to human mood disor-
ders, especially the effects on sleep and cognitive performance.
Selected ﬁndings from the past decade of human research related
to melanopsin phototransduction and physiology are summarized
in Table 1.
1.3.1. Pupillometry
The contribution of melanopsin to neurobehavioral responses
can be distinguished from that of other photoreceptors when expo-
sures to speciﬁc wavelengths, intensities, and durations of light
are tested. The pupillary light reﬂex (PLR) adjusts the diameter
of the pupil by light intensity, protecting the retina from dam-
age and aiding vision. To date, human studies show that blue but
not red wavelengths elicit ongoing constriction during stimulation,
ongoing constriction after cessation (i.e., post-illumination pupil-
lary response, PIPR), and that the human PLR driven by melanopsin
is most sensitive to short wavelength light but may  be potenti-
ated by longer wavelengths (Gamlin et al., 2007; Kankipati et al.,
2010; Kawasaki and Kardon, 2007; Mure et al., 2009). Although in
rodents, melanopsin contributes about three times more to steady
state pupil diameter than cones at high irradiances, rods, cones, and
melanopsin cells all contribute to the PLR (Hattar et al., 2003; Lucas
et al., 2003; Tsujimura et al., 2010). Although different populations
of melanopsin cells exist, the M1 type intrinsically photosensitive
retinal ganglion cells (ipRGCs) underlie both circadian photoen-
trainment and the pupillary light reﬂex (Schmidt et al., 2011),
making it possible to make inferences about the function of one
system by measuring the other. Pupillometry in humans is a poten-
tial tool for investigating “melanopsin-related disorders” (Gamlin
et al., 2007). Extended duration stimuli of speciﬁc narrow band
wavelengths can be used in a relatively fast and noninvasive way
in human studies to isolate the functioning of melanopsin, allow-
ing inferences about the relative sensitivity of melanopsin across
diagnostic groups (Do and Yau, 2010; Kardon et al., 2011). Poten-
tial clinical applications of pupillometry are broad, from diagnosis
of retinal diseases, to possibly discerning the role of melanopsin
photoreception in SAD (Kardon et al., 2011; Wilhelm, 2010).
1.3.2. Circadian photoentrainment
Although the etiology of SAD has not been determined, one main
hypothesis contends that SAD is due to a seasonal circadian phase
disturbance, and is discussed more thoroughly below (Lewy et al.,
2006). Hence, the role of melanopsin in circadian photoentrain-
ment has implications for this hypotheses of SAD. Data indicate
that, in speciﬁc conditions of photoentrainment in rodents, about
40–50% of the response is driven by melanopsin cells (Do and
Yau, 2010), although it is unclear if this translates to other non-
visual responses in humans. Melanopsin knockout mice, however,
have only subtle changes in their circadian rhythms, indicating that
rods and cones convey light information through the melanopsin
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ganglion cells for entrainment. Phase shifts in rhythms of human
melatonin in response to 460 nm light are two-fold greater than
those in response to 555 nm light at high irradiances, indicating
a primary role of melanopsin photoreception for human circadian
photoentrainment (Lockley et al., 2003).
1.3.3. Melatonin synthesis
Melanopsin could also play a role in SAD through the regulation
of melatonin. In both humans and animals, the pineal gland releases
melatonin at night in response to darkness and signals from the
circadian clock (Lewy, 2007; Nelson et al., 2010). Winter nights
result in a longer duration of melatonin, which is a biological signal
that triggers seasonal behaviors in mammals, such as changes in
feeding and sleeping (Schibler, 2007; Workman and Nelson, 2011).
Light acts to acutely suppress melatonin, and mice missing rods
and cones still exhibit suppression of melatonin (Lucas et al., 1999;
Panda et al., 2003), implying that melanopsin is involved in acute
melatonin suppression in mice. In humans, short wavelength light
between 446–477 nm is the most effective for acute suppression
of melatonin, indicating a primary role for melanopsin in mela-
tonin suppression (Brainard et al., 2001; Revell et al., 2010; Thapan
et al., 2001). Cone photoreceptors, in addition, appear to contribute
to human melatonin suppression at the beginning of light expo-
sure (Gooley et al., 2010). Both early and late responses to light in
humans may  be therapeutically important, and optimal light ther-
apy might employ both longer and shorter wavelengths to engage
cones as well as melanopsin (Brainard et al., 2001, 2008; Gooley
et al., 2010; Revell et al., 2010; Thapan et al., 2001).
1.3.4. Circannual rhythms
Many rhythms that recur annually, such as in the seasonally
breeding Siberian hamster, are driven by changes in day length
and the resulting increase in the duration of nightly melatonin syn-
thesis (see Schibler, 2007 for a review). In addition to melatonin,
other circadian markers of season that may  also be inﬂuenced by
melanopsin-mediated light input include photoperiod-dependent
patterns of gene expression in rodents (Sumova et al., 2003;
Tournier et al., 2003; Travnickova et al., 1996) and seasonal varia-
tions in the electrophysiological activity in the rodent central clock
that encode day length (VanderLeest et al., 2007). Given the role
of melanopsin in melatonin and circadian entrainment described
above, seasonal rhythms driven by circadian rhythms or photope-
riod would be similarly dependent on individual differences in
melanopsin functioning. In healthy humans, controlled laboratory
studies have shown that the melatonin rhythm as well as prolactin,
cortisol, body temperature and sleep are inﬂuenced by photoperiod
length (Wehr, 1991; Wehr et al., 1993). Those studies illustrated the
conservation of photoperiodic responsiveness of humans, although
it has been suggested that in industrialized societies, photoperiodic
responses may  be masked by higher ambient artiﬁcial light levels
Wehr et al., 1993). In contrast, one study found no seasonal change
in the nightly duration of melatonin release in controls, suggesting
that only some subgroups of individuals, notably those with SAD,
retained the lengthened duration of melatonin release seen in other
mammals (Wehr et al., 2001).
1.3.5. Sleep regulation
Since hypersomnia is a primary SAD symptom, the role of
melanopsin in sleep regulation may  be important. Extensive human
research has established that light has clear effects on (1) circa-
dian entrainment of sleep, (2) homeostatic sleep regulation, and (3)
acute light-induced effects on alertness. Animal research indicates
that melanopsin plays a role in some or all of this sleep regula-
tion and physiology. Melanopsin cells project to neural regions
involved in sleep regulation (Hattar et al., 2006) including the ven-
tral lateral pre-optic area (VLPO; Hannibal and Fahrenkrug, 2004;
Lu et al., 2000), and the superior colliculus (SC), which has been
implicated in the photic regulation of sleep (Gooley et al., 2003;
Miller et al., 1998). In nocturnal rodents, light during the dark
activity phase will acutely induce sleep, but in diurnal animals
and humans, short wavelength light has the expected opposite
effect of increased alertness. Knockouts, however, have signiﬁ-
cantly reduced acute light-induced activation of the VLPO and SC,
and do not exhibit acute sleep responses to light, or experience a
delay in such responses (Altimus et al., 2008; Do and Yau, 2010; Lupi
et al., 2008; Tsai et al., 2009). Melanopsin appears to be involved
in the physiological basis of the homeostatic sleep drive, since
melanopsin knockout mice exhibit reduced sleep duration and debt
(Tsai et al., 2009).
1.3.6. Alertness
Decrements in alertness are also relevant for depression,
although light has the opposite effect on nocturnal mice as in
diurnal humans. In mice, darkness is alerting during the light
phase, but this effect is delayed in melanopsin knockouts, indicating
that melanopsin participates in driving acute alertness responses
(Altimus et al., 2008; Tsai et al., 2009). These data lead to the
hypothesis that a melanopsin-mediated effect on alertness may
explain the role of melanopsin in SAD (Schmidt et al., 2011). Human
studies have found that light causes an acute increase in cognitive
performance and alertness (e.g., Badia et al., 1991; French et al.,
1990), especially short wavelength light (An et al., 2009; Cajochen
et al., 2005; Lockley et al., 2006; Phipps-Nelson et al., 2003; Revell
et al., 2010; Zaidi et al., 2007; Figueiro et al., 2007). Based on
spectral sensitivity, however, self-reported alertness ratings are
driven by a combination of photoreceptors whose contributions
may  vary across the day (An et al., 2009; Revell et al., 2010).
Although light may  increase alertness by suppressing melatonin
when it is released, other as yet unidentiﬁed process stimulating
the ascending arousal system and cortex are likely during the day
when melatonin is low (Lockley and Gooley, 2006).
1.3.7. Daily rhythm
Daily variations in melanopsin cell numbers, protein, and mRNA
have been observed in animals (Gonzalez-Menendez et al., 2009;
Hannibal et al., 2005; Sakamoto et al., 2004), although daily
variations in melanopsin-related functions may  also be due to
downstream processes in the melanopsin and circadian pathways.
In humans, it appears that a daily variation in the sensitivity of
the melanopsin pathway occurs, as reﬂected by the PIPR (Zele
et al., 2011), and melatonin suppression and iris constriction
(Figueiro et al., 2005). Objective measures of human cognitive
function in response to light are highest at night, after dusk (An
et al., 2009). The mechanism behind such daily variation is likely
to be due to an interaction between multiple photoreceptors, the
clock, and light input (Dacey et al., 2005; Wong et al., 2007). For
example, the peak period of melanopsin mRNA expression in rats
increases in duration under long day length conditions and is illu-
mination dependent (Mathes et al., 2007). It is possible that a light
sensitive transcription feedback loop controls melanopsin activity
(Hannibal et al., 2005), such that the effect of light on circadian,
neuroendocrine and neurobehavioral processes varies by time of
day. Consistent timing of measurement is therefore critical when
studying behavioral responses dependent on melanopsin.
2. SAD etiology
Although biological hypotheses of SAD have been reviewed else-
where (Lamont et al., 2007; Levitan, 2007; Rohan et al., 2009),
none have yet incorporated the recent ﬁndings regarding these
melanopsin-containing ganglion cells that regulate the biological
and behavioral responses to light. Seasonal changes in circadian
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rhythms and light responses in humans and animals can be healthy
or adaptive, but individuals with SAD may  experience a patho-
logical extreme of normal human seasonal variation (Magnusson,
2000). In seasonally breeding rodents, multiple biological rhythms
vary across the seasons, and such rodents may  have utility as poten-
tial animal models for SAD (Workman and Nelson, 2011). There is
evidence of seasonal variation in humans such as seasonal peaks
in birth rates, growth rate, cortisol, testosterone, pain thresholds,
alertness, sexual activity and conception, and behaviors such as
crime, suicide, all cause mortality, and rape (see Roenneberg and
Aschoff, 1990; Lam and Miron, 1991; Workman and Nelson, 2011).
Aschoff (1981) suggests that sociocultural factors and increasing
industrialization may  explain a decrease in amplitude of these sea-
sonal rhythms since the 1930s. The general U.S. population reports
a winter worsening of mood, increased appetite, longer sleep dura-
tion, and decreased energy and social interaction levels in winter
(Rosen et al., 1990). SAD is seen as the extreme case on a continuum
of seasonal variations in mood and behavior (Kasper et al., 1989).
In fact, some degree of seasonal depression may  have once been
adaptive as a means to save energy in winter, although wintertime
decrements in activity would be less adaptive in our current envi-
ronment (Eagles, 2004). Here we describe etiological hypotheses of
SAD, with a focus on the possible role of melanopsin in many of the
hypotheses.
2.1. Circadian hypotheses of SAD
2.1.1. Phase shift hypothesis
The phase shift hypothesis proposes that SAD occurs when circa-
dian rhythms are out of phase, shifted earlier or later, relative to the
sleep/wake cycle (Lewy, 2007). This hypothesis has been deﬁned as
the difference between a marker of circadian phase (i.e., DLMO) and
mid-sleep, or a misalignment in the phase angle between the cir-
cadian clock and the sleep/wake cycle. Although a majority (71%)
of SAD patients have delayed rhythyms (Lewy et al., 2006), approx-
imately half do not have signiﬁcantly different rhythms compared
to controls (46%; Eastman et al., 1993). This indicates that circa-
dian misalignment alone may  not explain SAD etiology. Morning
light therapy (or combined morning/evening light) appears supe-
rior to evening or midday light therapy administration (Terman
et al., 1989). When circadian misalignment is measured, treatment
to correct misalignment is associated with decreased depression
symptoms in SAD (Lewy, 2007), and the degree of change in mis-
alignment is associated with degree of improvement (e.g., Lewy
et al., 2006). It may  be that subgroups of individuals with SAD have
different directions and degrees of misalignment, perhaps due to
different genetic predispositions. Given the role of melanopsin in
circadian entrainment, and this evidence for circadian misalign-
ment in SAD, it is not surprising that melanopsin gene variations are
associated with changes in sleep timing and chronotype (Roecklein
et al., 2012), although these ﬁndings have not yet been replicated.
2.1.2. Photoperiod
The photoperiod hypothesis of SAD states that longer duration
of nocturnal melatonin release, due to longer nights in winter,
may  be a “circadian signal of change in season,” triggering depres-
sion (Wehr et al., 2001). Wehr et al. (2001) tested the photoperiod
hypothesis in SAD and healthy controls living in their usual envi-
ronment. Individuals with SAD had longer winter melatonin release
(30–48 min  in men  and women compared to themselves in sum-
mer), a seasonal variation not seen in healthy controls (Wehr et al.,
2001). Individuals with SAD did not have a signiﬁcant phase shift
compared to healthy controls in winter, but time of melatonin off-
set and midpoint was consistent with the phase shift hypothesis
(Wehr et al., 2001). It remains to be seen if regular light therapy dur-
ing winter can lead to shortened duration of melatonin release in
SAD, or if gene variations are associated with melatonin. In healthy
individuals, there can be large individual differences in nighttime
acute suppression of melatonin by light (Brainard et al., 1988). Fur-
ther, evening melatonin suppression by light is more effective in
winter (Owen and Arendt, 1992). Although the factors explaining
these seasonal and individual differences in light suppression of
melatonin are unknown, one possible explanation could be genet-
ically mediated differences in retinal sensitivity.
2.1.3. Retinal sensitivity
The retinal subsensitivity hypothesis proposes that normal
increases in retinal sensitivity in response to low light levels in
winter is impaired, leading the retina to be less sensitive than
necessary (Hebert et al., 2002; Reme et al., 1990). Whole retina
recording measures include electroocculography (EOG), and elec-
troretinography (ERG), under either scotopic conditions, reﬂecting
primarily rod responses, or photopic conditions, reﬂecting largely
cone driven responses.
2.1.3.1. Electroocculography. Two  studies found lower EOG  ratios
in SAD, which would reﬂect lower electrical potential and activity
if outside of the normal range (Lam et al., 1991; Ozaki et al., 1993).
The ﬁrst study to analyze season found that healthy individuals had
higher EOG ratios in winter compared to summer, a difference not
seen in SAD patients (Ozaki et al., 1995). This indicates that the up-
regulation thought to be required for low winter light levels was
not occurring in SAD, and that the lack of up-regulation could be
pathological in SAD. In SAD patients responding to one week of
winter light therapy, however, low EOG ratios did not rise to the
levels seen in controls (Ozaki et al., 1993). The underlying mecha-
nism behind EOG levels is still unclear, making conclusions difﬁcult
to draw from this type of recording.
2.1.3.2. Electroretinography. One study using scotopic ERG in
response to dim white light ﬂashes found that women with SAD had
lower ERG, but men  with SAD had higher ERG amplitude compared
to controls, while other studies did not ﬁnd this gender difference
(Lam et al., 1992). Both individuals with subsyndromal seasonal
affective disorder (S-SAD) (Hebert et al., 2002) and SAD (Hebert
et al., 2004) had lower rod sensitivity (i.e., scotopic ERG) in win-
ter compared to controls. This difference normalized in summer
and after treatment with light therapy (Hebert et al., 2004). The
photopic ERG may  also be decreased in SAD in winter, and does
not differ from controls after light therapy or in summer (Lavoie
et al., 2009). Recently, SAD and control participants were exposed
to 10,000, 100, and 5 lx light for one hour (Gagne and Hebert, 2011).
A signiﬁcant decrease in ERG following 10,000 lx 1 h exposures was
found in both summer and winter in SAD but not controls, and is
proposed as a biomarker of SAD, although the response was not spe-
ciﬁc to wavelength. In a recent study using different wavelengths,
ERGs were compared between SAD and control participants after
either a red or blue 1 h exposure (Gagne et al., 2011). ERGs were
signiﬁcantly lower after the blue stimuli, but SAD and controls did
not differ. There may  be other measures, such as chromatic pupil-
lometry (e.g., the PIPR, which is primarily driven by melanopsin
containing cells and not rods and cones), that are more sensitive
to melanopsin cell functioning than ERG, given that melanopsin
cells are only 1–2% of the ganglion cells in the retina (Provencio
et al., 1998) and would contribute less to whole retina recor-
ding responses like ERG. Considering synaptic connections through
bipolar cells from both rods and cones to the M1  (melanopsin type
1) cells involved in the pupillary light reﬂex and circadian photoen-
trainment (Schmidt et al., 2011), it stands to reason that deﬁcits in
the classical photoreceptors would impact melanopsin-mediated
functions as well.
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2.1.4. Sleep
Most individuals with SAD (80%) report hypersomnia (Kaplan
and Harvey, 2009). Despite reports of hypersomnia, studies have
not been able to identify changes in sleep architecture and sleep
regulation speciﬁc to SAD. Although some studies ﬁnd no differ-
ences in homeostatic drive, some evidence suggests a deﬁciency
in the homeostatic drive in SAD (Cajochen et al., 2000). Reports
of hypersomnia may  also reﬂect a desire for more sleep as a
result of disrupted sleep (Kaplan and Harvey, 2009). When mea-
sured actigraphically, individuals with SAD had decreased sleep
efﬁciency, daytime inactivity, greater time in bed, and a phase-
delay compared to healthy controls, but showed no increase in
actual time spent asleep (Winkler et al., 2005). Home actigraphy
and/or polysomnography may  help distinguish increased time in
bed from increased total sleep time in those reporting hypersom-
nia (Kaplan and Harvey, 2009). Another important aspect of sleep
in SAD may  be the timing of sleep, and resultant effects on circa-
dian phase. In healthy individuals, sleep durations of 9 h and later
morning wake times (3 h later) led to a signiﬁcant phase delay in the
timing of dim light melatonin onset (Burgess and Eastman, 2006).
When healthy individuals in the same study slept 6 h and woke at
their regular workday time, a phase advance was  observed, indi-
cating the importance of morning wake time and light exposure
for circadian entrainment. Perhaps individuals with SAD are most
similar to those in the 9 h sleep condition, and are phase delayed as
a result, suggesting an interaction between circadian entrainment
and sleep.
2.1.5. Neurotransmitters
The role of neurotransmitters including serotonin and dopamine
(DA) has been investigated in SAD. Variations in DA related genes,
such as the D4 receptor gene variation (DRD4 VNTR), are associated
with SAD, speciﬁcally with eating behavior, carbohydrate craving,
and body mass index (Levitan et al., 2004, 2006). Because DA is
additionally involved in modulating retinal sensitivity and neuro-
biological responses to light, it is possible that SAD etiology could be
explained by variations in dopaminergic signaling (Levitan, 2007),
independently of melanopsin phototransduction. Future studies
may  investigate an association between reduced ERG in SAD, as
described above, and the DRD4 variation in SAD (Levitan, 2007).
More complex interactions between DA, melanopsin, and reti-
nal sensitivity are possible given that DA is involved in light and
dark adaptation in the retina (Levitan, 2007; Witkovsky, 2004),
melatonin can inhibit DA release, and DA can inhibit melatonin pro-
duction in the retina (Cahill and Besharse, 1991). DA agonists in the
retina cause increased melanopsin mRNA expression (Sakamoto
et al., 2005), suggesting the possibility that DA variations may
impact melanopsin signaling through regulation of OPN4 mRNA
expression. DA also may  modulate ipRGC signaling (Van Hook et al.,
2012), and ipRGCs appear to project to dopaminergic intraneu-
rons in the retina, thereby contributing to visual signaling (Zhang
et al., 2012). Hypodopaminergic states in the retina could change
DA mediated signaling in cones (Witkovsky, 2004), and given the
contribution of cone signaling to melanopsin containing ganglion
cells (Schmidt et al., 2011), it is theoretically possible that DA
gene variations could impact melanopsin cell functioning through
cone-driven processing. Although disruptions in serotonergic neu-
rotransmission are likely to represent an underlying vulnerability
in SAD (e.g., Neumeister et al., 2001), it is less likely that serotonin
would interact with melanopsin signaling or retinal sensitivity. The
neurotransmitter hypothesis of SAD has been well described else-
where (Neumeister et al., 2001).
2.1.6. Hyperphagia
Individuals with SAD are more likely to report increased
appetite, food intake (i.e., hyperphagia), weight gain, and
carbohydrate craving. Further, 17–26% of those diagnosed with
SAD present with a comorbid eating disorder diagnosis, partic-
ularly Bulimia Nervosa (BN) (Lam et al., 2001). Interestingly, in
women with comorbid SAD and BN, light therapy led to a decrease
in binge/purge episode frequency, but was  more effective in alle-
viating mood symptoms (Lam et al., 2001). Although light therapy
may  improve mood, which in turn decreases eating symptomology,
it is also possible that increased light levels directly affect eating
behavior through modulation of hypothalamic pathways involved
in metabolic and energy homeostasis or via circadian physiology.
Neuroanatomical studies have demonstrated that melanopsin cells
project to the lateral hypothalamus, a region involved in regulating
energy homeostasis, suggesting that light may  have direct effects
on eating and/or metabolism (Hattar et al., 2003).
2.1.7. Interactions
Individual differences in light sensitivity could be a function of
retinal sensitivity, the sensitivity of the circadian clock to light,
reduced light input, or a combination of these factors. Circadian
variations in the sensitivity of melanopsin signaling are likely to
reﬂect a complex feedback loop between central and retinal clocks
(Hastings et al., 2003; Zele et al., 2011). For example, an individ-
ual with SAD may  have decreased melanopsin sensitivity, which
may  only be an issue in winter when environmental light levels
are lower and input is decreased. The complexity of the system
is increased considering that environmental factors interact with
biological factors.
2.2. Environment
The environmental trigger for SAD is most likely the change
in the daily light/dark cycle due to a change in season or latitude
(Rosenthal et al., 1984). The temporal sequence of symptom onset
in SAD is most closely linked to photoperiod than other climatic
variables (e.g., minutes of sunshine, global radiation, cloud cover;
e.g., Young et al., 1997). In England, not only are actimetrically-
measured light levels higher in summer overall, but evening blue
light is 3 times higher in summer compared to winter (Thorne et al.,
2009). Research shows that individuals with SAD, however, receive
the same amount of winter light compared to controls (Guillemette
et al., 1998), and more in summer compared to controls (Graw
et al., 1999). Therefore, individuals with SAD may  be more sen-
sitive to seasonal changes in natural light decreases in winter, or
more vulnerable to this natural seasonal change (Guillemette et al.,
1998).
2.3. Summary
Given the reliance of circadian, neuroendocrine and neuro-
behavioral physiology on environmental light, and the roles of
these functions in SAD, we  hypothesize that winter environmen-
tal light input triggers a susceptibility to low light levels. Since
all individuals living at high latitudes are exposed to seasonal
changes in photoperiod, predispositions must explain why  only
some develop SAD. Future research is needed to determine if abnor-
mal  retinal sensitivity may  constitute year-round or winter-only
changes in retinal sensitivity, or it may  be that certain individ-
uals are less sensitive to RHT input centrally. One possibility
is that low light levels in the winter may  fall below a thresh-
old in either melanopsin-speciﬁc, or general retinal sensitivity,
which is required for euthymic functioning. Such a threshold may
be biologically mediated by individual differences in the circa-
dian photoreceptor system as a whole, or melanopsin functioning
speciﬁcally. Such individual differences in retinal sensitivity may
have consequences for central nervous system targets involved in
circadian, neuroendocrine and neurobehavioral functions, leading
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Table  2
Summary of future directions in research.
Study descriptions
Pupillometry designed to isolate the sensitivity of melanopsin cells (i.e.,
Post Illumination Pupil Response; PIPR)
Consider time of assessment, circadian phase of participant, season
and/or photoperiod
Adjust for age-related changes in lens density
Review methodological considerations (Wilhelm, 2010)
Carefully chose duration, intensity (irradiance) and wavelength given
speciﬁc experimental questions
Evaluate the blue-light hazard over the duration of exposure typical in
light therapy for SAD
Test whether pupillometry or variations in genes involved in circadian
entrainment can predict response to light therapy
Determine if long wavelengths prior to broad-spectrum light therapy can
potentiate response in light therapy
Notes: See Section 3 for elaboration.
to symptoms typically seen in SAD such as sleep and eating changes
as well as circadian phase shifts.
3. Future directions
The potential relationship between melanopsin, light, and SAD
has been under-explored, in general. Table 2 details the follow-
ing recommendations for areas of future research. With our recent
and growing understanding of melanopsin containing ipRGCs, and
the hypothesis for how melanopsin may  play a role in seasonal
depression, the next step is to describe a method of action for
assessing the model with hypothesis testing. To date, much of the
research on melanopsin physiology, especially as it might relate
to seasonal variations, has been on healthy animals, and healthy
humans, and very little in SAD, highlighting the need for future
studies in healthy humans, those with SAD, and possibly in ani-
mal  models of SAD (Workman and Nelson, 2011). Importantly,
the contributions of ipRGCs to mood in humans, or animal mod-
els of depression, have not yet been described at the level of detail
known for other ipRGC contributions (Schmidt et al., 2011). In test-
ing whether or not melanopsin photoreception mediates seasonal
variations in responses to light in SAD, critical issues include the
nature of light stimuli, measurement of responses, and study design
issues. Speciﬁcally, pupillometry designed to isolate the sensitivity
of melanopsin cells from rods and cones, which has been employed
in studies of retinal pathology, may  lead to breakthroughs in our
understanding of SAD.
3.1. Methodological considerations
Variables to consider in pupillometry include time of assess-
ment, patient age, stimulus background and intensity, eye of
exposure versus recording, sufﬁcient spatial and temporal resolu-
tion in pupillometry recording equipment, and careful analysis of
outcome data including appropriate handling of amplitude, blinks,
and multiple observations per participant (Wilhelm, 2010). In addi-
tion, factors affecting the autonomic nervous system such as noise,
arousal level, cognitive load, and medications should be controlled
(Markwell et al., 2010). The effect of light stimuli on the retina
can be affected by head movements, blinks, pupil constriction,
and light transmission through the ocular media (Brainard et al.,
1997, 2001; Gaddy et al., 1993). As the human lens ages, trans-
mission of short wavelengths of light is reduced (Brainard et al.,
1997; Lerman, 1987), so efforts to control for these age effects
are necessary. Given that the sensitivity of the human visual sys-
tem differs from the circadian system, it is currently more useful
to quantify irradiance or photon density within a speciﬁed band
of wavelengths rather than illuminance (An et al., 2009; Brainard
Fig. 1. Responsitivity of melanopsin compared to other photopigments. Notes: Log
relative sensitivity scaled to ﬁt an A1-based photopigment nomogram identifying
482 nm as the wavelength at which melanopsin-containing ganglion cells are most
sensitive in the non-human primate. S – short, M – medium, and L – long wavelength
cone cells.
Reprinted by permission from Macmillan Publishers Ltd: Nature, (Dacey et al., 2005),
copyright (2005).
et al., 2001; Gooley et al., 2010). Illuminance measures reﬂect the
wavelength sensitivity of the human visual system to light and can
signiﬁcantly misrepresent photic input for nonvisual responses. A
number of nascent models have proposed a basis for light measure-
ment related to circadian, neuroendocrine and neurobehavioral
responses. For example, the recently described “melanopic” photo-
metric measure of light intensity predicts melanopsin-driven pupil
and circadian responses to polychromatic light in mice with only
ipRGC photoreceptors (rd/rd cl mice; Enezi et al., 2011).
3.2. Chromatic pupillometry
Because current measures of retinal function like ERG measure
electrical activity across the entire retina, the effect of relatively
sparse melanopsin cells may  be quite low unless stimuli are care-
fully designed to reﬂect melanopsin responses. For example, the
post-illumination pupil response (PIPR) is likely to be predomi-
nately mediated by melanopsin cells as opposed to rods or cones,
leading to methods designed to elicit melanopsin responses (Park
et al., 2011). Studies using monochromatic light stimuli may  want
to approach 460 nm as opposed to 480 nm to optimally stimulate
melanopsin-driven responses, as 460 nm is the wavelength maxi-
mally driving sustained melanopsin driven pupil responses to long
duration stimuli (McDougal and Gamlin, 2010; Mure et al., 2009),
as well as prolonged exposures for acute melatonin suppression
(Brainard et al., 2001; Thapan et al., 2001). The spectral proﬁle of
photoreceptors (i.e., rods, cones, and ipRGCs) in the primate retina
is shown in Fig. 1, demonstrating that narrow bandwidth stimuli
are needed to minimize “bleed-through” of a stimulus intended to
stimulate only ipRGCs. In SAD, it is more likely that sustained light
input, from the environment across the day, is more etiologically
signiﬁcant than brief stimuli. In addition, it may  be more ecolog-
ically valid to use polychromatic light stimuli when evaluating
circadian, neuroendocrine and neurobehavioral responses. Finally,
cones appear to provide strong early input and subsequently adapt,
while melanopsin cells provide sustained input during continuous
illumination without evidence for adaptation (Dollet et al., 2010;
Gooley et al., 2010). In mice, rods appear to play a large role in
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circadian photoentrainment, in addition to cones, so it is important
to consider rod contributions when trying to isolate the responses
of ipRGCs (Altimus et al., 2010).
3.3. Assessment timing
Beyond careful control of stimuli parameters, the timing of light
experiments is critical because of the existence of circadian varia-
tions in melanopsin cell sensitivity. As described above, melanopsin
cells display a daily variation in a number of factors that may  affect
sensitivity (Gonzalez-Menendez et al., 2009; Hannibal et al., 2005;
Sakamoto et al., 2004; Zele et al., 2011). It is not yet known if
efforts to standardize timing across participants should be based
on the timing of ﬁrst light exposure at awakening, or based on cir-
cadian time. Each would imply different means of controling for
variables known to inﬂuence melanopsin functioning including cir-
cadian time, previous light exposure, and current environmental
photoperiod.
3.4. Blue light hazard
Concerns have been raised about the safety of both experimen-
tal and therapeutic light exposures (Gagne et al., 2011; Reme et al.,
1996; Terman, 2009). Since light devices vary in their spectral com-
position, it is always prudent to assure light dosages given to the
human eye fall within safe exposure limits. According to national
and international standards, one of the deﬁned risks of photochem-
ical retinal injury, the blue light hazard, is highest between 400 and
500 nm (ACGIH, 2010; ANSI, 2005, ICNIRP, 1997). Researchers can
use the published standards to calculate the safe limit of duration
and irradiance for stimuli (Brainard et al., 2001, 2008; Glickman
et al., 2006; West et al., 2011). Values for absolute irradiance and
wavelength of a light source can be determined with a spectropho-
tometer. Measured irradiance then should be integrated using a
blue-light hazard weighting function. Standards are based on expo-
sure durations from 1 ns to 8 h (ACGIH, 2010; ANSI, 2005, ICNIRP,
1997). Since light therapy for SAD is typically used daily during fall
and winter for 30–60 min, it is within the dosimetric range of these
standards. Absolute irradiance measurements also permit experi-
menters to determine the photon density at each wavelength from
a light source, critical for accurately interpreting the physiolog-
ical, behavioral and therapeutic responses to light (Revell et al.,
2010). Hence, it is important for SAD researchers to provide detail
on the spectrum and irradiance of their light sources (Anderson
et al., 2009; Revell et al., 2010; West et al., 2011).
3.5. Optimizing light therapy for SAD
The discovery and characterization of the melanopsin path-
way triggered interest in using lights with wavelengths centered
around the blue portion of the visible spectrum, or broad bandwidth
light with increased intensity in the blue-appearing wavelengths.
Studies have established that blue or blue-enriched lights at signiﬁ-
cantly lower light irradiances, yield similar rates of improvement in
SAD as traditional bright white light therapy units (Anderson et al.,
2009; Glickman et al., 2006; Meesters et al., 2011; Strong et al.,
2009), and are able to phase advance rhythms (Smith et al., 2009).
Outstanding questions include whether the melanopsin cells are
primary in mediating light therapy’s effects, and whether it may
be possible to potentiate the effects of light therapy by using long
wavelength light ﬁrst (Gooley et al., 2010; Mure et al., 2009; Rollag,
2008). Furthermore, it is possible that gene variations could be used
to predict the timing, duration, risk of side effects, and potential
beneﬁt of light therapy, opening the door to individualized treat-
ment prescriptions in the future.
3.6. Conclusions
The new research on melanopsin and the circadian, neuroen-
docrine and neurobehavioral repsonses to light has provided
an opportunity to understand the physiology behind individual
differences in responses to seasonal changes in light levels. It
appears that melanopsin sequence variations may  increase risk for
mood disorders with a seasonal pattern. Further, seasonal vari-
ations in sleep and chronotype may be mediated by different
thresholds of melanopsin-based sensitivity to light. Both of these
SNP-association studies, however, deserve replication. Determin-
ing if the melanopsin pathway is involved in mood and sleep
disorders may  help improve treatment outcomes by determining
the time, duration, and wavelength for optimal light therapy. In
addition, it may  be possible to identify subgroups of individuals
with SAD for whom melanopsin functioning may  or may  not be
important, allowing for individually tailored treatment prescrip-
tions.
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